Pharma in Focus research update on Australia's pharmaceutical market

The Australian pharmaceutical market was valued at around $9 billion in 2009 and includes both domestic manufacturers and large pharmaceutical companies, with the latter having a direct base in the country through R&D and marketing, says a new reprt frm Pharma in Focus. Among foreign players, Pfizer, AstraZeneca, Sanofi-Aventis and Novartis dominated the Australian pharmaceutical market in 2009

According to the 2008 AIHW (Australian Institute of Health and Welfare) report, high life expectancy (second only to Japan) and an increasingly aged population has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. Approximately one in every five adult Australians (nearly 4 million people) has some or the other disability and more than 1 million people need assistance with their daily activities.

The Australian Pharmaceutical Market Outlook to 2015 makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share, sales forecast and competitive landscape for the major players in Australia. Furthermore, the report highlights the key market and R&D trends that may influence treatment sales, with a thorough analysis of the competitive dynamics of leading brands in Australia. This will enable the reader to identify growth trends, key drug classes and leading players through to 2015.